{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:52:52Z","timestamp":1787014372580,"version":"build-2736575974"},"reference-count":45,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1196900"],"award-info":[{"award-number":["1196900"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sustained\u2010release (SR) tapentadol was listed on Australia's Pharmaceutical Benefits Scheme (PBS) in 2014 for chronic severe pain requiring long\u2010term opioid treatment. Dispensings have increased since listing despite declining trends in other PBS\u2010listed opioids. Preferential prescribing of SR opioids may increase the risk of dependence and accidental overdose, particularly when used to treat acute pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To explore the quality use of publicly subsidised tapentadol in Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We examined annual initiation rates and patterns of use of tapentadol (SR) in the dispensing records of a 10% random sample of PBS\u2010eligible Australians (2014\u20132021). We used national tapentadol sales data to assess the proportion of sales attributable to the PBS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tapentadol initiation increased from 2014, peaking at 7.5\/1000 adult population in 2019 before declining to 5.3\/1000 in 2021. We identified 63\u2009766 new users between 2014 and 2020, of whom 92.8% discontinued in the first year following initiation, 58.0% had only a single dispensing and 34.3% had no other opioids dispensed in the 3 months before or after initiation. 27.8% of new users were dispensed tapentadol on the same day as potentially interacting medicines. There was a sustained drop in the proportion of sales attributable to the PBS from June 2020 onwards, from an average of 69.1%, to 63.9% of pack sales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patterns of use suggest tapentadol (SR) is generally used for short duration. Although most tapentadol sold in Australia is subsidised, there is evidence of a shift towards private sales.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/imj.16335","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T04:49:41Z","timestamp":1706762981000},"page":"941-950","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Quality use of publicly subsidised tapentadol in Australia: a population\u2010based analysis"],"prefix":"10.1111","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2371-1441","authenticated-orcid":false,"given":"Ximena","family":"Camacho","sequence":"first","affiliation":[{"name":"School of Population Health, Faculty of Medicine and Health UNSW Sydney  Sydney New South Wales Australia"},{"name":"NHMRC Centre of Research Excellence in Medicines Intelligence  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-4997","authenticated-orcid":false,"given":"Andrea L.","family":"Schaffer","sequence":"additional","affiliation":[{"name":"School of Population Health, Faculty of Medicine and Health UNSW Sydney  Sydney New South Wales Australia"},{"name":"NHMRC Centre of Research Excellence in Medicines Intelligence  Sydney New South Wales Australia"},{"name":"The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Brett","sequence":"additional","affiliation":[{"name":"School of Population Health, Faculty of Medicine and Health UNSW Sydney  Sydney New South Wales Australia"},{"name":"NHMRC Centre of Research Excellence in Medicines Intelligence  Sydney New South Wales Australia"},{"name":"Clinical Pharmacology and Toxicology St Vincent's Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8730-8910","authenticated-orcid":false,"given":"Nicole","family":"Pratt","sequence":"additional","affiliation":[{"name":"NHMRC Centre of Research Excellence in Medicines Intelligence  Sydney New South Wales Australia"},{"name":"Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences University of South Australia  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6326-4711","authenticated-orcid":false,"given":"Nicholas A.","family":"Buckley","sequence":"additional","affiliation":[{"name":"NHMRC Centre of Research Excellence in Medicines Intelligence  Sydney New South Wales Australia"},{"name":"Biomedical Informatics and Digital Health, Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Henry","sequence":"additional","affiliation":[{"name":"NHMRC Centre of Research Excellence in Medicines Intelligence  Sydney New South Wales Australia"},{"name":"Institute for Evidence Based Healthcare, Bond University  Gold Coast Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7137-6855","authenticated-orcid":false,"given":"Sallie\u2010Anne","family":"Pearson","sequence":"additional","affiliation":[{"name":"School of Population Health, Faculty of Medicine and Health UNSW Sydney  Sydney New South Wales Australia"},{"name":"NHMRC Centre of Research Excellence in Medicines Intelligence  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/11589080-000000000-00000"},{"key":"e_1_2_9_3_1","unstructured":"Palexia SR Product Information.In TGA Product and Consumer Medicine Information. 2020."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2018-0027"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0660-4"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618760939"},{"key":"e_1_2_9_7_1","unstructured":"US Food and Drug Administration [Internet].FDA Drug Safety Communication: FDA Warns About Several Safety Issues With Opioid Pain Medicines; Requires Label Changes [Cited 2022 Jun 30]. Available from URL:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-several-safety-issues-opioid-pain-medicines-requires"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2017.1416440"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107697"},{"key":"e_1_2_9_10_1","unstructured":"Pharmaceutical Benefits Scheme [Internet].Schedule of Pharmaceutical Benefits Summary of Changes (Effective 1 June 2014) [Cited 2022 Jul 4]. Available from URL:https:\/\/www.pbs.gov.au\/publication\/schedule\/2014\/06\/2014-06-01-general-schedule-soc.pdf"},{"key":"e_1_2_9_11_1","unstructured":"The Pharmaceutical Benefits Scheme [Internet].Tapentadol [Cited 2022 Sep 22]. Available from URL:https:\/\/www.pbs.gov.au\/medicine\/item\/10091D-10092E-10094G-10096J-10100N"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.3365"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.8071"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2022.06.013"},{"key":"e_1_2_9_15_1","unstructured":"Department of Health.Opioid Analgesics: Drug utilisation Sub\u2010Committee (DUSC). Canberra: Australian Government Department of Health."},{"key":"e_1_2_9_16_1","unstructured":"COAG Health Council.Communique 31 October \u2013 1 November 2019. 2019."},{"key":"e_1_2_9_17_1","unstructured":"Pharmaceutical Society of Australia [Internet].Medicine Safety to be the 10th National Health Priority Area [Cited 2022 Oct 17]. Available from URL:https:\/\/www.psa.org.au\/medicine-safety-to-be-the-10th-national-health-priority-area\/"},{"key":"e_1_2_9_18_1","unstructured":"Australian Commission on Safety and Quality in Health Care.Medication Without Harm \u2013 WHO Global Patient Safety Challenge: Australia's Response Australian Commission on Safety and Quality in Health Care. 2019."},{"key":"e_1_2_9_19_1","unstructured":"Therapeutic Goods Administration [Internet].Prescription Opioids: What Changes are Being Made and Why [Updated 22 June 2021; Cited 2022 May 25]. Available from URL:https:\/\/www.tga.gov.au\/prescription-opioids-what-changes-are-being-made-and-why"},{"key":"e_1_2_9_20_1","unstructured":"NPS MedicineWise [Internet].Opioids: New and Amended PBS Listings [Updated 01 July 2020; Cited 2021 Oct 11]. Available from:https:\/\/www.nps.org.au\/radar\/articles\/opioids-new-and-amended-pbs-listings"},{"key":"e_1_2_9_21_1","unstructured":"Pharmaceutical Benefits Scheme [Internet].Schedule of Pharmaceutical Benefits Summary of Changes (June 2020) [updated 1 June 2020; Cited 2022 May 25]. Available from URL:https:\/\/www.pbs.gov.au\/publication\/schedule\/2020\/06\/2020-06-01-general-soc.pdf"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8"},{"key":"e_1_2_9_24_1","article-title":"The changing face of Australian data reforms: impact on pharmacoepidemiology research","volume":"6","author":"Oliveira CJ","year":"2021","journal-title":"Int J Popul Data Sci"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3931"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50552"},{"key":"e_1_2_9_27_1","unstructured":"Australian Medicines Handbook [Internet].Tapentadol [Cited 2021 Oct 15]. Available from URL:https:\/\/amhonline.amh.net.au\/chapters\/analgesics\/drugs-pain-relief\/opioid-analgesics\/tapentadol"},{"key":"e_1_2_9_28_1","volume-title":"Opioids in Pain Management","author":"Therapeutic Guidelines","year":"2021"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"e_1_2_9_30_1","unstructured":"Australian Bureau of Statistics.TABLE 59. Estimated Resident Population By Single Year Of Age Australia [time series spreadsheet]. December 2021."},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3945"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5443"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15448"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2011.06.100232"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067746"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109292"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/00048674221079740"},{"key":"e_1_2_9_39_1","volume-title":"Medication Without Harm \u2013 WHO Global Patient Safety Challenge","author":"World Health Organization","year":"2017"},{"key":"e_1_2_9_40_1","article-title":"Stepping up controls on opioid use in Australia: evaluating the impact of tightened prescribing restrictions and introducing half\u2010pack sizes","author":"Koch F","journal-title":"Med J Aust"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1071\/PY20270"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4329"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12966"},{"key":"e_1_2_9_44_1","unstructured":"Australian Institute of Health and Welfare [Internet].Canberra: Admitted Patient Care 2020\u201321 [Cited 2022 Jul 14]. Available from URL:https:\/\/www.aihw.gov.au\/reports-data\/myhospitals\/sectors\/admitted-patients"},{"key":"e_1_2_9_45_1","unstructured":"Australian Institute of Health and Welfare [Internet].Canberra: Australia's Hospitals at a Glance [Updated 22 June 2022; Cited 2022 Jul 14]. Available from URL:https:\/\/www.aihw.gov.au\/reports\/hospitals\/australias-hospitals-at-a-glance\/contents\/impact-of-covid-19-on-hospital-care"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/2380084420986766"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.16335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T05:04:47Z","timestamp":1718600687000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.16335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/imj.16335"],"URL":"https:\/\/doi.org\/10.1111\/imj.16335","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2023-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}